The potential of proton beam radiation therapy in gastrointestinal cancer

Acta Oncologica

Volumn 44, Issue 8, 2005, Pages 896-903

  Ask, Anders ^a   Johansson, Bengt ^b   Glimelius, Bengt ^c,d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEAM THERAPY; ESOPHAGUS CARCINOMA; GASTROINTESTINAL CARCINOMA; HOSPITAL CARE; HUMAN; LIVER CARCINOMA; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE; RECTUM CARCINOMA; REVIEW; SWEDEN;

GASTROINTESTINAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SWEDEN;

EID: 28844491745     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500355926     Document Type: Review

References (65)

1. Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003;www.sos.se.
2. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
3. Albertsson M. Chemoradiotherapy of esophageal cancer. Acta Oncol 2002;41:118-23.
4. Ask A, Albertsson M, Järhult J, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in oesophageal cancer. Acta Oncol 2003;42:462-75.
5. Tai P, Van Dyk J, Yu E, Battista J, Stitt L, Coad T. Variability of target volume delineation in cervical esophageal cancer. Int J Radiat Oncol Biol Phys 1998;42:277-88.
6. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-75.
7. Bedford JL, Viviers L, Guzel Z, Childs PJ, Webb S, Tait DM. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 2000;57:183-93.
8. Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP, Webb S. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 2001;61:157-63.
9. Wu VW, Sham JS, Kwong DL. Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol 2004;77:568-72.
10. Tait DM. Multi-modality treatment in oesophageal cancer: a curse for radiotherapy progress. Radiother Oncol 2004;73:115-7.
11. Okawa T, Dokiya T, Nishio M, Hishikawa Y, Morita K. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Int J Radiat Oncol Biol Phys 1999;45:623-8.
12. Koyama S, Tsujii H, Yokota H, Hotta S, Miyo Y, Fukutomi H, et al. Proton beam therapy for patients with esophageal carcinoma. Jpn J Clin Oncol 1994;24:144-53.
13. Tsunemoto H, Ishikawa T, Morita S, Kitagawa T, Tsujii H. Indications of particle radiation therapy in the treatment of carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1992;22:321-4.
14. Isacsson U, Lennernäs B, Grusell E, Jung B, Montelius A, Glimelius B. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. Int J Radiat Oncol Biol Phys 1998;41:441-50.
15. Graffman S, Jung B. Clinical trials in radiotherapy and the merits of high energy protons. Acta Radiol Ther Phys Biol 1970;9:1-23.
16. Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003;42:387-410.
17. Talbäck M, Stenbeck M, Rosén M, Glimelius B. Cancer survival in Sweden. Acta Oncol 2003;42:637-59.
18. Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;23:4509-17.
19. Janunger K, Hafström Lo, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-26.
20. Cunningham D, Allum WH, Stenning SP, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005:Abstr 4001.
21. MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
22. Leong T, Willis D, Joon DL, Condron S, Hui A, Ngan SY. 3D conformal radiotherapy for gastric cancer-results of a comparative planning study. Radiother Oncol 2005;74:301-6.
23. Glimelius B. Has progress been made in gastrointestinal cancer treatment? Acta Oncol 2002;41:115-7.
24. Smalley SR, Gunderson L, Tepper J, Martenson JA, Minsky BD, Willett C, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002;52:283-93.
25. White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am 2004;13:675-84, ix-x.
26. White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005;12:214-21.
27. Yamaguchi K, Nakamura K, Kobayashi K, Nakano K, Konomi H, Mizumoto K, et al. ERT following IORT improves survival of patients with resectable pancreatic cancer. Hepatogastroenterology 2005;52:1244-9.
28. Ihse I, Andersson R, Ask A, Ewers SB, Lindell G, Tranberg KG. Intraoperative radiotherapy for patients with carcinoma of the pancreas. Pancreatology 2005;5:38-42.
29. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
30. Glimelius B. Pancreatic and hepatobiliary cancers: adjuvant therapy and management of inoperable disease. Ann Oncol 2000;11:153-9.
31. Wilkowski R, Thoma M, Weingandt H, Duhmke E, Heinemann V. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP 2005;6:216-30.
32. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314-27.
33. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538-44.
34. Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004;136:1003-11.
35. Zurlo A, Lomax A, Hoess A, Bortfeld T, Russo M, Goitein G, et al. The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors. Int J Radiat Oncol Biol Phys 2000;48:277-88.
36. Ragnhammar P, Hafström Lo, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
37. Glimelius B. Palliative treatment of patients with colorectal cancer. Scand J Surg 2003;92:74-83.
38. Johnson PJ. Primary liver tumours. In: Souham IT RL, Hohenberger P, Horiot J-C, editors. Oxford Textbook of Oncology. 2nd ed. Oxford: Oxford University Press; 2002. p. 1627-40.
39. Glimelius B. Liver metastases. In: Souhami IT RL, Hohenberger P, Horiot J-C, editors. Oxford Textbook of Oncology. 2nd ed. Oxford: Oxford University Press; 2002. p. 1663-80.
40. Ingold JA, Reed GS, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol 1965;93:200.
41. Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 1996;14:722-8.
42. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150-5.
43. Blomgren H, Lax I, Göranson H, Kræpelien T, Nilsson B, Näslund I, et al. Radiosurgery for tumors in the body: Clinical experience using a new method. J Radiosurg 1998;1:63-75.
44. Matsuzaki Y. The efficacy of powerful proton radiotherapy for hepatocellular carcinoma-Long term effects and QOL. Ann Cancer Res Ther 1998;8:9-17.
45. Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994;106:1032-41.
46. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-46.
47. Tokuuye K, Y A, Hashimoto T, et al. Clinical results of proton radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;383:(abstr).
48. Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004;59:1468-76.
49. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92.
50. Glimelius B. Balancing gains and costs in radiation therapy of rectal cancer. Dis Colon Rectum 2005; in press.
51. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005;23:6126-31.
52. Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005;23:1847-58.
53. Jansson-Frykholm G, Påhlman L, Glimelius B. Combined chemo- and radiotherapy vs radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001;50:427-34.
54. Glimelius B. Chemoradiotherapy for rectal cancer-is there an optimal combination? Ann Oncol 2001;12:1039-45.
55. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-104.
56. Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:665-77.
57. Diaz-Gonzalez JA, Calvo FA, Cortes J, de La Mata D, Gomez-Espi M, Lozano MA, et al. Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. Int J Radiat Oncol Biol Phys 2005;61:1378-84.
58. Chapet O, Romestaing P, Mornex F, Souquet JC, Favrel V, Ardiet JM, et al. Preoperative radiotherapy for rectal adenocarcinoma: Which are strong prognostic factors? Int J Radiat Oncol Biol Phys 2005;61:1371-7.
59. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Muldner A, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005;23:1350-7.
60. Wiig JN, Poulsen JP, Tveit KM, Olsen DR, Giercksky KE. Intra-operative irradiation (IORT) for primary advanced and recurrent rectal cancer, a need for randomised studies. Eur J Cancer 2000;36:868-74.
61. Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM, et al. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2000;48:219-26.
62. Frykholm-Jansson G, Isacsson U, Sintorn K, Montelius A, Jung B, Påhlman L, et al. Preoperative radiotherapy in rectal carcinoma-aspects of adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 1996;35:1039-48.
63. Duthoy W, De Gersem W, Vergote K, Boterberg T, Derie C, Smeets P, et al. Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 2004;60:794-806.
64. Isacsson U, Montelius A, Jung B, Glimelius B. Comparative treatment planning between proton and x-ray therapy in locally advanced rectal cancer. Radiother Oncol 1996;41:263-72.
65. Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003;42:800-8.